** U.S.-listed shares of Israel-based drug developer PolyPid PYPD.O fell 4.7% to $2.75
** Company, which develops therapies to improve surgical outcomes, posts quarterly loss of $1.13 per share vs analysts' estimate loss of 88 cents
** Says independent monitoring board recommended to conclude late-stage study of experimental drug upon enrollment of 800 patients
** PYPD is testing the treatment to prevent surgical site infections in patients undergoing a type of abdominal cancer surgery
** Expects to report data from the late-stage in the second quarter of 2025 and plans to submit a marketing application to the FDA if the study meets the main goal
** In the last 12 months, stock has fallen 48.7%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.